BiotechTube
Advanced Cell Diagnostics

Advanced Cell Diagnostics

Newark, United States· Est.
acdbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $90M

Overview

Advanced Cell Diagnostics (ACD) is a leader in spatial biology, providing a critical technology platform for visualizing gene expression at the single-cell level within its morphological context. Its core RNAscope technology is widely adopted in academic, pharmaceutical, and diagnostic research for biomarker discovery, validation, and translational pathology. The company operates primarily as a tools and services provider, generating revenue from reagent sales, assay kits, and collaborative partnerships. Its strategic value lies in enabling precision medicine research by linking molecular data to tissue architecture.

OncologyNeuroscienceImmunologyInfectious Disease

Technology Platform

RNAscope, a proprietary in situ hybridization (ISH) platform using a patented double-Z probe design and branched DNA (bDNA) signal amplification for highly sensitive and specific single-molecule RNA visualization within intact cells and tissues.

Funding History

3
Total raised:$90M
Series C$50M
Series B$25M
Series A$15M

Opportunities

The rapid growth of the spatial biology market and the increasing need for tissue-contextual molecular data in both research and clinical diagnostics present a major expansion opportunity.
Leveraging Bio-Techne's resources to accelerate the development of FDA-cleared IVD assays and companion diagnostics represents a significant high-value growth vector.

Risk Factors

Intense competition from newer spatial genomics technologies threatens market share in the research tools segment.
The lengthy, costly, and uncertain regulatory pathway for clinical diagnostic assay approval poses a significant hurdle to capturing the full diagnostic market opportunity.

Competitive Landscape

ACD faces competition from companies offering alternative spatial analysis technologies, including 10x Genomics (Visium, Xenium), NanoString (GeoMx DSP, CosMx SMI), Akoya Biosciences (PhenoImager), and Lunaphore (COMET). Competition centers on multiplexing capability, sensitivity, resolution, workflow simplicity, and data analysis integration.

More companies in Diagnostics & Precision Medicine →More companies in United States →